EUCTR2005-004500-37-IT进行中（未招募）不适用
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients with Venous Stasis Ulcers - ND
SIGMA-TA0 个研究点目标入组 72 人开始时间: 2006年8月30日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients will be enrolled in this study only if they meet all of the following criteria 1.Male or female, between 18 and 79 years of age, with evidence of venous insufficiency as documented by venous duplex scanning or impedance plethysmography; 2.At least one venous leg ulceration index ulcer with a surface area between 3 and 30 cm2; and with a distance of at least 2.5 cm between the index ulcer and any other active ulcer; 3.Index ulcer stable for at least 6 weeks before enrollment; and 4.Informed Consent Form signed by the patient.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will be enrolled in this study only if they meet none of the following criteria 1.Have the designated ulcer below the malleolus, on the foot, or above the base of the knee; 2.Have clinical evidence of active infection on the index ulcer; 3.Use of any experimental drug, or participation in any clinical study, within the 60 days before enrollment; 4.Use of systemic or topical steroidal therapy, immunotherapy, or cytotoxic chemotherapy within the 60 days before enrollment; 5.History of adverse reaction to any ingredients of the study medication; 6.Clinically significant abnormalities on screening laboratory tests complete blood count including differential and platelets, coagulation, chemistry, and urinalysis ; 7.Clinically significant neurological, cardiovascular, respiratory, hepatic, renal, metabolic and dermatologic disease other than venous ulcers; 8.Current or former malignancy; 9.Arterial disorder resulting in ulcerated ulcers; 10.Arterial insufficiency evidenced by an ankle brachial index ABI of 0.8. Subjects with an ABI 1.2 must have a toe brachial index of 0.6 or a supine transcutaneous oxygen measurement 30 mm Hg; 11.Diabetes mellitus; 12.Pregnant or lactating breastfeeding women. A serum pregnancy test will be performed at screening for female patients of childbearing potential; 13.Women who have had menarche but have not completed menopause 1 year or longer without a menstrual period , have not been surgically sterilized bilateral tubal ligation or hysterectomy , do not have a partner with documented sterility including vasectomy and are not using adequate contraception if sexually active; For this study adequate contraception means sexual abstinence or the use of combined oral contraceptives. 14.Any condition or situation likely to cause the patient to be unable or unwilling to participate in study procedures, participate in all scheduled study assessments, or to complete the study; and 15.Previous participation in this study
研究者
相似试验
进行中（未招募）
1 期
Study to test the efficacy and safety of Padsevonil as adjunctive treatment of focal-onset seizures in adults with drug-resistant epilepsyFocal-Onset SeizuresMedDRA version: 20.0Level: LLTClassification code 10065337Term: Focal epilepsySystem Organ Class: 100000004852EUCTR2017-003200-48-LTCB Biopharma SPR411
进行中（未招募）
不适用
A study to evaluate the efficacy of different doses of LY3009104 therapy compared to placebo in patients with Rheumatoid Arthritis who are on ongoing methotrexate background therapy.MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2010-022504-42-HUEli Lilly and Company270
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart FailureHeart FailureEUCTR2013-002893-35-SKTrevena Inc.500
进行中（未招募）
1 期
This is a randomized, double-blinded, Placebo controlled trial with a 3-part treatment period that will evaluate the efficacy and safety of up to 70 weeks of treatment with tildacerfont in subjects with classic Congenital adrenal hyperplasia (CAH) who have elevated blood hormones at baselineClassic Congenital Adrenal HyperplasiaMedDRA version: 20.0Level: LLTClassification code 10010323Term: Congenital adrenal hyperplasiaSystem Organ Class: 100000004850EUCTR2019-004764-22-PLSpruce Biosciences, Inc.72
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Dose-Loading Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Inadequately Controlled, Moderate to Severe, Chronic Low Back PaiModerate to severe, chronic, low back pain (LBP) that is not adequately controlled by standard pain therapyMedDRA version: 9.1Level: LLTClassification code 10024891Term: Low back painEUCTR2009-009857-17-BEJanssen-Cilag International NV360